...15,  vTv said the Elevage study of azeliragon...
...for developing Alzheimer’s, and the idea that azeliragon...
...conditions was based on the observations that azeliragon’s...

...drug.vTv misses endpoint in Alzheimer’s-diabetes studyvTv Therapeutics Inc. (NASDAQ:VTVT) said the Phase II Elevage study of azeliragon...
...O’Neill, CMO and EVP of R&D of Sarepta Therapeutics Inc. (NASDAQ:SRPT). Jeff Cranmer Entresto, sacubitril/valsartan (LCZ696) azeliragon (TTP488, PF-04494700, PF-4494700) Singlera AnGes Emendo...

...other indications. (A) Last year, vTv Therapeutics Inc. (NASDAQ:VTVT) halted two Phase III trials of azeliragon...
...ALS, AD Ph Ib Other Receptor for advanced glycation endproducts (RAGE) vTv Therapeutics Inc. (NASDAQ:VTVT) Azeliragon...

...vTv Therapeutics Inc. (NASDAQ:VTVT) said azeliragon (TTP488) missed the co-primary endpoints compared with placebo in Part...
...Part B, azeliragon missed the co-primary endpoints in a prespecified subgroup of patients with maximal azeliragon...
...Daily Living Inventory (ADCS-ADL) Status: Additional Phase III data Milestone: NA Jaime De Leon azeliragon (TTP488, PF-04494700, PF-4494700) vTv...

...vTv Therapeutics Inc. (NASDAQ:VTVT) said it will discontinue clinical trials of azeliragon (TTP488) after the Alzheimer’s...
...once-daily 5 mg oral azeliragon or placebo for 18 months. On Part A's co-primary endpoints, azeliragon...
...Study-Activities of Daily Living Inventory (ADCS-ADL) Status: Phase III discontinued Milestone: NA Brian Moy azeliragon (TTP488, PF-04494700, PF-4494700) vTv...

...vTv Therapeutics Inc. (NASDAQ:VTVT) said it will discontinue clinical trials of azeliragon (TTP488) after the Alzheimer’s...
...once-daily 5 mg oral azeliragon or placebo for 18 months. On Part A's co-primary endpoints, azeliragon...
...glucokinase (GCK; GK) activator. vTv was off $0.16 to $3.26 on Monday. Brian Moy azeliragon (TTP488, PF-04494700, PF-4494700) vTv...

...NASDAQ:VTL) ELAD system Acute liver failure Ph III VTL-308 data 3Q18 vTv Therapeutics Inc. (NASDAQ:VTVT) Azeliragon...

...about 800 patients with mild Alzheimer’s disease in the Phase III STEADFAST trial of azeliragon (TTP488...
...of Daily Living Inventory (ADCS-ADL). vTv plans to report data from the trial next year. Azeliragon...
...advanced glycation endproducts (RAGE) antagonist. vTv Therapeutics LLC (NASDAQ:VTVT), High Point, N.C. Product: Azeliragon ( TTP488...

...the model. vTv Therapeutics Inc. has the RAGE antagonist azeliragon ( TTP488 ; PF-04494700 ; PF-4494700...

...trial in 399 patients with mild to moderate AD showed that once-daily 5 mg oral azeliragon...
...trial (see BioCentury, Nov. 12, 2012). Top-line data from the Phase III STEADFAST trial of azeliragon...
...late 2017 or early 2018. vTv Therapeutics Inc. (NASDAQ:VTVT), High Point, N.C. Product: Azeliragon ( TTP488...